Alector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...
Alector (ALEC) recently reported that its experimental therapy latozinemab did not meet the main efficacy goal in a late-stage trial for frontotemporal dementia. As a result, multiple follow-up ...
The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...
This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...
Alector (NASDAQ:ALEC) shares extended post-market losses to drop ~50% in the premarket on Wednesday after the ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...
Alector said it will cut its workforce nearly in half after discontinuing trials for latozinemab, an investigational treatment for dementia. The biopharmaceutical company said it would reduce its ...
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...
Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback